A disease-specific measure would allow for more sensitive assessment of the impact of MDS interventions. 6, 7 With the input of MDS patients, caregivers, providers, and QoL experts, we have created the Quality of Life in Myelodysplasia Scale version 1 (QUALMS-1), 8 a new MDS-specific QoL measure developed in the era of disease-modifying agents. Individual and combined focus groups were conducted with members of the MDS community associated with the Dana-Farber Cancer Institute to identify MDS-relevant QoL domains and associated question topics. A draft 38-item scale was then constructed, using an algorithm that weighted the overall score by incorporating a greater number of questions from more highly ranked domains (Table 1) .
Not unexpectedly, fatigue was ranked as the most important domain. None of the 12 domains was ranked significantly differently by patients/caregivers vs providers. The 2 groups ranked only 5 of 60 question topics differently ("too tired for routine tasks": providers higher, P 5 .05; "limited support beyond the family": providers higher; P 5 .02"; "organizing life around transfusion/doctor appointments": providers higher, P 5 .03; "bruising": patients/ caregivers higher, P 5 .05; "anger over diagnosis": providers higher, P 5 .03). The high level of agreement in the rankings of domains and question topics between MDS patients/caregivers and providers suggests that the QoL of MDS patients is compromised, and in a reliably measureable fashion.
We next piloted the QUALMS-1 with a new cohort of MDS patients at the Dana-Farber Cancer Institute (n 5 20) including behavioral coding followed by a structured cognitive interview using Jobe's framework. 9 We interviewed patients individually and reassessed after every 5, refining the QUALMS-1 after each group. By patient 17, saturation was achieved: no questions were found to be confusing, upsetting, irrelevant, or intrusive. The mean time to complete the instrument was a minimally burdensome 7.5 minutes. We are currently field testing the QUALMS-1 in a larger, international cohort of patients (n 5 180) to assess its validity, reliability, and responsiveness.
We hope that, once validated, the QUALMS-1 will impact the lives of MDS patients by facilitating the approval of disease-altering therapies, especially given the increasing focus by the FDA on patientreported outcomes.
10 It will also permit physicians to more specifically advise patients about the risks and benefits of new therapies in the context of their current QoL. Finally, the implementation of the QUALMS-1 will provide more precise measurement of QoL in these patients to detect actual differences between treatments being tested, if these truly exist. Contribution: All authors collected or analyzed data, and all authors wrote and approved the manuscript. 1 This estimate is in sharp contrast to the small number of recognized clinical cases that may be explained at least in part by the extremely prolonged incubation periods associated with human prion disease and the possibility that the barrier to infection is lower in lymphoreticular tissue than in brain, 2 leading to subclinical infection.
A sensitive and specific blood-based assay for vCJD infection, though urgently needed, has been elusive because abnormal prion protein (PrP) levels are extremely low in blood and chemically identical normal PrP is in large excess. Previously, we demonstrated a prototype assay that captured and enriched disease-associated PrP from whole blood using stainless steel powder, achieving impressive analytical (10 210 dilution of vCJD-affected brain) and diagnostic (71% of vCJD-infected patient blood samples) sensitivity. 3 To explore the assay's specificity and hence suitability for screening exposed and at-risk populations, we tested 5000 blood samples from the American Red Cross in which, because of minimal BSE exposure, no true positives would be expected (US normals). No samples tested positive (100% specificity; 95% CI: 99.93%-100%) ( Table 1 ). The high specificity was reflected in a smaller, healthy UK cohort (UK normals). The assay's positive likelihood ratio indicates true positives are more than 7000 times as likely as false positives; the negative likelihood ratio indicates true negatives are more than 3 times as likely as false negatives. Finally, we tested a small blind panel of unaffected and vCJD patient samples. Seven of 10 vCJD patient samples tested positive (70% sensitivity), reconfirming but not refining our previous sensitivity estimate.
A remaining question is whether the assay can detect sub-or preclinical vCJD-affected individuals. Although it has been suggested that asymptomatic individuals would have particularly low concentrations of abnormal PrP, preclinical blood involvement 4 Whole blood samples were incubated overnight in buffer containing stainless steel powder, as previously described. 3 The powder was heat treated and sequentially incubated with biotinylated anti-PrP antibody, NeutrAvidin-HRP, and chemiluminescent substrate. Samples were scored reactive if the mean signal from 3 replicates exceeded an on-plate negative control cutoff. Repeat-reactive samples were considered positive for vCJD; nonreactive and single-reactive samples were considered negative for vCJD. Anonymous blood samples from unaffected blood donors were obtained from the American Red Cross (US normals) and the National Health Service Blood and Transplant service of England and Wales (UK normals). Positive control samples consisted of 0.1% wt/vol vCJD-infected brain homogenate in whole unaffected human blood (vCJD spikes) and were used to preserve scarce stocks of endogenous vCJD patient samples (vCJD patients). Clopper and Pearson's "exact" method was used for confidence intervals of proportions. Likelihood ratios and their confidence intervals were calculated using Haldane's correction and a derived approximation for risk ratios.
HRP, horseradish peroxidase.
